This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Aucentra Therapeutics Pty Ltd. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Innovations by Sarah Al Haj Diab
Introduction
Sarah Al Haj Diab is an accomplished inventor based in St. Peters, Australia. She has made significant contributions to the field of therapeutic agents, particularly in the development of inhibitors for protein kinases. Her work is particularly relevant in the treatment of various cancers characterized by aberrant CDK activity.
Latest Patents
Sarah holds a patent for "Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents." This patent describes a novel class of inhibitors that are useful in treating cell proliferative diseases, including lung, breast, brain, ovary, prostate, colorectal cancers, and leukemias. The inhibitors have a general structure that allows them to target specific CDK enzymes, which are often over-expressed in these conditions. She has 1 patent to her name.
Career Highlights
Sarah is currently associated with Aucentra Therapeutics Pty Ltd, where she continues her research and development efforts. Her innovative approach to drug design has positioned her as a key player in the pharmaceutical industry.
Collaborations
Sarah has collaborated with notable colleagues, including Shudong Wang and Yi Long, to advance her research and contribute to the scientific community.
Conclusion
Sarah Al Haj Diab's work exemplifies the impact of innovative thinking in the field of medicine. Her contributions to therapeutic agents are paving the way for new treatments for serious health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile